Is Stevanato Group S.p.A. (STVN) Overvalued?
We dive into why Stevanato Group S.p.A. (STVN) could be considered overvalued on 2026-07-28, based on AAII’s Value Score and Grade.Jenna Brashear
Stock Evaluator: Stevanato Group S.p.A. (STVN)
Stevanato Group S.p.A. STVN
$19.85
-0.35
-1.73%
July 31, 2026 4:00:02 PM
EST
Volume: 204,076
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Commentary & Analysis
Which Is a Better Investment, AbCellera Biologics Inc. or Stevanato Group S.p.A. Stock?
Learn more about whether AbCellera Biologics Inc. or Stevanato Group S.p.A. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Stevanato Group S.p.A.’s (STVN) Stock Is Up 5.92%
As of Thursday, June 25, Stevanato Group S.p.A.’s STVN share price has surged by 5.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Stevanato Group S.p.A.’s (STVN) Stock Is Up 6.97%
As of Wednesday, June 17, Stevanato Group S.p.A.’s STVN share price has surged by 6.97%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Stevanato Group S.p.A.’s (STVN) Stock Is Down 5.95%
As of Thursday, May 07, Stevanato Group S.p.A.’s STVN share price has dipped by 5.95%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | STVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,419.1 | $1,790.4 | 68% |
|
| Shares Out (Mil) | 314.8 | 94.8 | 84% |
|
| Institutional Ownership | 98.3% | 90.0% | 78% |
|
| Float (Mil) | 19.1 | 69.9 | 28% |
|
| Beta | 0.78 | 1.20 | 46% |
|
| Avg Daily Volume (000s) | 318 | 814 | 52% |
|
| Price Change (52-week) |
(20.4%) | 80.2% | 31% |
|
| Growth | STVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.5% | 7.8% | 64% |
|
| Net Income (5yr) | 11.3% | (13.7%) | 57% |
|
| EPS (5yr) | 8.5% | 0.7% | 44 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.6%) | (15.0%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | $0.147 | $0.700 | $0.834 | |
| Month Ago EPS | $0.149 | $0.705 | $0.838 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.153 | $0.703 | $0.854 | |
| Year/Year Chg | 27.8% | 16.9% | 66.9% | |
| Financials | STVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,387 | $785 | 55% |
|
| Net Income (TTM) (Mil) | $163 | ($14) | 66% |
|
| EPS (TTM) | $0.597 | ($0.200) | 55% |
|
| Operating Cash Flow (TTM) (Mil) | $302 | $53 | 65% |
|
| Net Cash Flow (TTM) (Mil) | $26 | ($4) | 65% |
|
| Long-Term Debt (Q1) (Mil) | $373 | $270 | 56% |
|
| Enterprise Value (Q1) (Mil) | $5,422 | $2,444 | 64% |
|
| Valuation | STVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.07 | 2.92 | 66% |
|
| P/E | 33.8 | 43.7 | 73% |
|
| Dividend Yield | 0.3% | 0.0% | 61% |
|
| PEG (5yr hist) | 4.0 | 5.3 | 83% |
|
| Ratios | STVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 29.2% | 47.6% | 34% |
|
| Net Margin | 11.7% | (2.9%) | 67% |
|
| ROA | 5.9% | (2.8%) | 76% |
|
| ROE | 9.9% | (4.5%) | 57% |
|
| Liabilities to Assets | 40.8% | 43.0% | 31% |
|
| F-Score | 5 | 5 | 51% |
|
Stevanato Group S.p.A. did not pass any screens on 7/31/2026.
